Literature DB >> 6262095

Buprenorphrine: demonstration of physical dependence liability.

J Dum, J Bläsig, A Herz.   

Abstract

This study was designed to assess the dependence-producing capacity of the opiate partial agonist, buprenorphine. Rats chronically treated with buprenorphine for 4 days showed only very weak signs of withdrawal upon cessation of buprenorphine treatment or upon challenge with naloxone, although complete tolerance had developed to the drug at this time. However, more intense withdrawal could be induced when buprenorphine treatment was followed by substitution treatment with morphine. Even one injection of morphine given 12 h after the last buprenorphine treatment enabled the precipitation of withdrawal with naloxone. Naloxone could not precipitate signs of withdrawal in naive rats treated with this dose of morphine. Thus, contrary to some claims in the literature, buprenorphine, like other opiate agonists and partial agonists, induces dependence. The fact that only few signs of withdrawal are seen in direct dependence tests, probably reflects the slow dissociation of the drug from the receptor - which probably limits the intensity of withdrawal by preventing the rapid uncovery of the receptor upon discontinuance of treatment with the drug or upon injection of an antagonist. In addition, the maximum degree of dependence induced by buprenorphine - in comparison to pure agonists is limited, like that of other partial agonists.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6262095     DOI: 10.1016/0014-2999(81)90163-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

1.  [Not Available].

Authors:  I Jurna
Journal:  Schmerz       Date:  1987-07       Impact factor: 1.107

Review 2.  Buprenorphine-containing treatments: place in the management of opioid addiction.

Authors:  Susan E Robinson
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human.

Authors:  Michael M Morgan; MacDonald J Christie
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

4.  Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats.

Authors:  S S Negus; M J Picker; L A Dykstra
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys.

Authors:  H Fukase; K Fukuzaki; T Koja; R Nagata; S E Lukas
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

6.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

7.  In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions.

Authors:  J E Dum; A Herz
Journal:  Br J Pharmacol       Date:  1981-11       Impact factor: 8.739

8.  Stimulation of avoidance behavior by buprenorphine in rats.

Authors:  H E Shannon
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Expression of BDNF and TrkB Phosphorylation in the Rat Frontal Cortex During Morphine Withdrawal are NO Dependent.

Authors:  Danil I Peregud; Alexander A Yakovlev; Mikhail Yu Stepanichev; Mikhail V Onufriev; Leonid F Panchenko; Natalia V Gulyaeva
Journal:  Cell Mol Neurobiol       Date:  2015-09-07       Impact factor: 5.046

10.  A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.

Authors:  D Andrew Tompkins; Michael T Smith; Miriam Z Mintzer; Claudia M Campbell; Eric C Strain
Journal:  J Pharmacol Exp Ther       Date:  2013-11-13       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.